Equities

SoftOx Solutions AS

SoftOx Solutions AS

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (NOK)0.112
  • Today's Change0.004 / 3.70%
  • Shares traded4.59m
  • 1 Year change-95.76%
  • Beta--
Data delayed at least 15 minutes, as of May 08 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

SoftOx Solutions AS is a Norway-based medtech and biotech company, that develops products to help fight infections from viruses, biofilm resistance and antimicrobial resistance. It is a developer of infection control solutions for disinfection, wound care and the respiratory tract. The current business segments can be divided into: Wounds, Disinfection and Respiratory. SoftOx Solutions is engaged in the development of a range of products that can be classified as either medical devices or medicinal products for human use. SoftOx’s product portfolio includes such products as SafeDes+, a hand disinfectant for irritated, compromised and eczematous skin. The Company has several subsidiaries, including SoftOx Disinfection AS, SoftOx Defense Solutions AS and SoftOx Denmark AS.

  • Revenue in NOK (TTM)6.98m
  • Net income in NOK-42.08m
  • Incorporated2012
  • Employees--
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Scandion Oncology A/S0.00-61.41m53.19m4.00--1.09-----1.53-1.530.001.200.00----0.00-63.25-45.09-76.67-52.65------------0.0158------48.89------
Pila Pharma AB1.46m-9.93m55.19m1.00--8.29--37.73-0.5304-0.53040.07670.280.1513--6.111,463,020.00-102.68-108.88-122.66-121.45-127.88-42.67-678.73-1,577.64---159.470.104---22.21--62.92------
Orphazyme A/S0.00-40.83m55.91m1.00--2.50-----737.75-737.750.00403.340.00----0.00-68.42-76.08-94.18-105.34------------0.00------32.00------
PCI Biotech Holding ASA2.99m-20.32m61.51m7.00--1.58--20.57-0.5443-0.54430.08011.050.0556--0.6848427,142.80-37.78-36.44-41.97-40.14-----679.43-1,055.43----0.0081---37.05-20.7863.13------
Spago Nanomedical AB (publ)1.20m-42.22m63.58m13.00--1.50--52.86-0.3818-0.38180.01150.18820.0093--5.7492,538.46-32.61-20.19-35.38-20.97247.55---3,509.81-4,853.45--------14.14---7.72------
Double Bond Phrmcutcl Intrntnl AB (publ)1.37m-17.33m64.65m10.00--11.52--47.18-0.1837-0.18370.01360.05560.1016--18.59137,033.00-128.49-80.90-198.98-106.45-241.22-686.41-1,265.24-1,360.03---217.550.00--10.25135.07-14.36------
Abera Bioscience AB0.00-16.72m66.46m----11.07-----1.24-1.240.000.3910.00-------115.63-79.43-149.06-96.11--------------------13.73------
Coegin Pharma AB0.00-27.97m66.71m----5.12-----2.67-2.670.000.64040.00-------125.24-122.02-201.53-154.70-----------170.65--------20.60------
ViroGates A/S8.75m-18.96m69.13m10.00--2.59--7.90-6.12-6.121.612.640.26530.26543.15558,300.00-57.47-46.58-63.01-52.0978.8377.91-216.66-238.018.56-23.890.2376---45.0110.98-25.40------
Prolight Diagnostics AB (publ)0.00-27.74m69.46m----0.2001-----0.0984-0.09840.000.6946-----------------------------------------13.84--
SoftOx Solutions AS6.98m-42.08m70.38m--------10.08-1.98-1.980.3286-0.01270.081--1.60---48.81-50.83-82.20-64.58-----602.91-646.670.1745-3.45-----1.8810.0640.85--39.43--
Combigene AB5.54m-35.66m73.25m8.00--0.6291--13.21-1.80-1.800.285.880.0398--2.63693,015.00-25.58-13.00-26.56-14.58-----643.32-58.77----0.00---79.23268.58-479.27---24.02--
ExpreS2ion Biotech Holding AB8.80m-95.97m76.06m28.00--1.25--8.65-2.12-2.120.18951.190.0832--9.91---90.72-64.80-113.72-77.46-109.74-1.94-1,090.91-532.25----0.0045--43.07-0.156119.07--19.90--
Immunovia AB (publ)1.21m-260.68m78.51m11.00--1.80--64.79-6.06-6.060.02760.96480.007558.2314.96110,181.80-160.93-41.33-194.89-44.24-5,523.76-7,553.76-21,512.13-20,879.292.03--0.1675--37.5536.48-84.09---50.93--
Chosa Oncology AB72.99k-23.94m79.09m----4.15--1,083.60-0.3524-0.35240.00130.26840.003--0.013---96.68-51.96-178.66-61.92-----32,798.63-708.47---97.97-----98.21--28.33------
Biosergen AB0.00-27.03m86.30m3.00--7.45-----0.4007-0.40070.000.04180.00----0.00-131.31---217.09----------------------32.25------
Data as of May 08 2024. Currency figures normalised to SoftOx Solutions AS's reporting currency: Norwegian Krone NOK
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.